Editas Medicine (EDIT)
(Delayed Data from NSDQ)
$3.19 USD
+0.23 (7.77%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Company Summary
Cambridge, MA-based Editas Medicine is a development-stage genome editing biotech, that makes medicines to treat serious diseases using its proprietary genome editing platform based on the unique Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. Though the company’s discovery efforts target several disease areas, ocular diseases and engineered cell medicines are two such zones where its pipeline is most mature.
Editas has been traded publicly since February 2016. Currently, it has no marketed drug in its portfolio.
Editas underwent massive strategic reprioritization where it decided to discontinue internal investments in the ...
Company Summary
Cambridge, MA-based Editas Medicine is a development-stage genome editing biotech, that makes medicines to treat serious diseases using its proprietary genome editing platform based on the unique Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. Though the company’s discovery efforts target several disease areas, ocular diseases and engineered cell medicines are two such zones where its pipeline is most mature.
Editas has been traded publicly since February 2016. Currently, it has no marketed drug in its portfolio.
Editas underwent massive strategic reprioritization where it decided to discontinue internal investments in the company’s inherited retinal disease (IRD) programs, including EDIT-101 for Leber Congenital Amaurosis 10 (LCA10) and EDIT-103 for rhodopsin-associated autosomal dominant retinitis pigmentosa (RHO-adRP). Editas Medicine is currently looking for partnerships for the further development of its IRD programs.
It has also discontinued internal investments in the company’s wholly-owned multiplexed edited iPSC-derived iNK cell programs, including EDIT-202 for solid tumors, looking for partnerships for the same as well.
In January 2023, Editas announced entering into a definitive agreement with Shoreline Biosciences to co-develop EDIT-202. Subsequently, the company prioritized reni-cel (formerly EDIT-301) as their lead candidate for non-malignant hematologic diseases, such as severe SCD and TDT. In August 2023, the company entered into a licensing agreement with Vor Bio, granting Vor Bio a non-exclusive license for the development of ex vivo Cas9 gene-edited hematopoietic stem cell (HSC) therapies for the treatment and/or prevention of hematological malignancies.
In December 2023, Editas signed a licensing agreement granting Vertex a non-exclusive license to utilize its Cas9 gene editing technology for ex vivo gene editing medicines targeting the BCL11A gene in the fields of SCD and TDT, including Casgevy.
With no marketed products in its portfolio, Editas only generates collaborations and other research and development revenues. Editas generated total revenues of $78 million in 2023 compared with $20 million recorded in 2022.
General Information
Editas Medicine, Inc
11 Hurley Street
Cambridge, MA 02141
Phone: 617-401-9000
Fax: NA
Web: http://www.editasmedicine.com
Email: ir@editasmed.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 9/30/2024 |
Exp Earnings Date | 11/1/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.76 |
Current Year EPS Consensus Estimate | -2.98 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/1/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 2.96 |
52 Week High | 11.69 |
52 Week Low | 2.91 |
Beta | 1.99 |
20 Day Moving Average | 2,275,770.50 |
Target Price Consensus | 13.86 |
4 Week | -14.93 |
12 Week | -39.81 |
YTD | -68.51 |
4 Week | -18.14 |
12 Week | -42.61 |
YTD | -75.89 |
Shares Outstanding (millions) | 82.48 |
Market Capitalization (millions) | 263.10 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | -46.43% |
vs. Previous Quarter | -7.89% |
vs. Previous Year | -82.23% |
vs. Previous Quarter | -54.80% |
Price/Book | 1.13 |
Price/Cash Flow | NA |
Price / Sales | 3.92 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -62.61 |
3/31/24 | -47.34 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -42.31 |
3/31/24 | -33.46 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 3.85 |
3/31/24 | 4.60 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 3.85 |
3/31/24 | 4.60 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -288.59 |
3/31/24 | -239.36 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -288.59 |
3/31/24 | -239.36 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -288.59 |
3/31/24 | -239.36 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 2.82 |
3/31/24 | 3.58 |
9/30/24 | NA |
6/30/24 | NA |
3/31/24 | NA |
9/30/24 | Pending Next EPS Report |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 0.00 |
3/31/24 | 0.00 |